MAPT and Alzheimer disease: Tau-PET has shown excellent diagnostic accuracy and strong associations with both concurrent and longitudinal cognitive decline, outperforming established AD biomarkers like amyloid-PET and structural magnetic resonance imaging across the clinical continuum of AD1–7.